

UNAUDITED FINANCIAL RESULTS
FOR THE QUARTER ENDED 30TH SEPTEMBER, 2002

Rs in millions

		Quarter Ended		Half Year Ended		Year Ended
		30.09.2002	30.09.2001	30.09.2002	30.09.2001	31.03.2002 (Audited)
1	Net Sales & Income from Operations	3943.4	3410.6	7972.9	6402.4	14005.1
2	Other Income	40.9	79.2	88.7	127.5	283.6
3	Total Expenditure					
	a) (Increase) / decrease in Stock-in - trade	11.6	100.9	(201.2)	(46.6)	(850.9)
	b) Consumption of Materials	1793.1	1468.3	3771.9	3006.0	6907.5
	c) Staff Cost	158.4	149.2	355.2	303.4	632.5
	d) Other Expenditure	998.9	934.9	2242.9	1796.6	4272.1
4	Interest	1.7	4.7	4.0	7.2	21.0
5	Depreciation	67.5	47.5	137.5	95.0	212.8
6	Profit (+) / Loss (-) before Tax (1+2-3-4-5)	953.1	784.3	1751.3	1368.3	3093.7
7	Provision for Taxation	216.5	180.0	408.4	320.0	742.5
8	Net Profit (+) / Loss (-) after tax (6-7)	736.6	604.3	1342.9	1048.3	2351.2
9	Paid-up Equity Share Capital	599.7	599.7	599.7	599.7	599.7
10	Reserves excluding Revaluation Reserves (as per balance-sheet of previous accounting year)					8197.0
11	Earning per Share * Not Annualised	*12.28	*10.08	*22.39	*17.48	34.62
12	Aggregate of Non-Promoter Shareholding	36044237	35843463	36044237	35843463	36044037
	- Number of Shares	60.10	59.77	60.10	59.77	60.10
	- Percentage of Shareholding					

Notes:

- 1 Provision for tax includes deferred taxation
- 2 The Company is exclusively in the pharmaceutical business segment
- 3 The figures of the previous year have been regrouped to render them comparable with the figures of the current year.
- 4 The above results were taken on record at the meeting of the Board of Directors held on 22nd October, 2002.

By order of the Board
For CIPLA LIMITED

Mumbai

22nd October, 2002.

Dr. Y. K. Hamied
Chairman & Managing Director